Future research could focus on: 1) investigating HRR mutation prevalence in GIST through large - scale sequencing and its prognostic significance; 2) using in - vitro experiments to determine if HRD - associated BRCA deficiency impacts KIT mutations or signaling pathways; 3) optimizing PARP inhibitor application in HRR - mutated GIST, including timing, dosage, combinations, and adverse reaction prevention. Here, KIT is linked to gastrointestinal stromal tumor.